Literature DB >> 15337696

Norepinephrine transporter-deficient mice exhibit excessive tachycardia and elevated blood pressure with wakefulness and activity.

Nancy R Keller1, André Diedrich, Martin Appalsamy, Sunti Tuntrakool, Suzanna Lonce, Charlene Finney, Marc G Caron, David Robertson.   

Abstract

BACKGROUND: Norepinephrine (NE) is a primary neurotransmitter of central autonomic regulation and sympathetic nerve conduction, and the norepinephrine transporter (NET) is crucial in limiting catecholaminergic signaling. NET is sensitive to antidepressants, cocaine, and amphetamine. NET blockade often is associated with cardiovascular side effects, and NET deficiency is linked to tachycardia in familial orthostatic intolerance. METHODS AND
RESULTS: We telemetrically monitored NET-deficient (NET(-/-)) mice to determine the cardiovascular effects of reduced NE reuptake. Mean arterial pressure was elevated in resting NET(-/-) mice compared with NET(+/+) controls (103+/-0.6 versus 99+/-0.4 mm Hg; P<0.01), and corresponding pressures increased to 122+/-0.3 and 116+/-0.3 mm Hg (P<0.0001) with activity. Heart rate was also greater in resting NET(-/-) mice (565+/-5 versus 551+/-3 bpm; P<0.05), and genotypic differences were highly significant during the active phase (640+/-5 versus 607+/-3 bpm; P<0.0001). Conversely, the respiratory rate of resting NET(-/-) mice was dramatically reduced, whereas increases after the day/night shift surpassed those of controls. Plasma catecholamines in NET(-/-) and NET(+/+) mice were as follows: NE, 69+/-8 and 32+/-7; dihydroxyphenylglycol, 2+0.4 and 17+/-3; epinephrine, 15+/-3 and 4+/-0.6; and dopamine, 13+/-4 and 4+/-1 pmol/mL. Catechols in urine, brain, and heart also were determined.
CONCLUSIONS: Resting mean arterial pressure and heart rate are maintained at nearly normal levels in NET-deficient mice, most likely as a result of increased central sympathoinhibition. However, sympathetic activation with wakefulness and activity apparently overwhelms central modulation, amplifying peripheral catecholaminergic signaling, particularly in the heart.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337696     DOI: 10.1161/01.CIR.0000141804.90845.E6

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

1.  Rab11 supports amphetamine-stimulated norepinephrine transporter trafficking.

Authors:  Heinrich J G Matthies; Jessica L Moore; Christine Saunders; Dawn Signor Matthies; Lynne A Lapierre; James R Goldenring; Randy D Blakely; Aurelio Galli
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

2.  Hepatic and renal mechanisms underlying the osmopressor response.

Authors:  Tu H Mai; Emily M Garland; André Diedrich; David Robertson
Journal:  Auton Neurosci       Date:  2017-01-27       Impact factor: 3.145

Review 3.  Minireview: Dopaminergic regulation of insulin secretion from the pancreatic islet.

Authors:  Alessandro Ustione; David W Piston; Paul E Harris
Journal:  Mol Endocrinol       Date:  2013-06-06

4.  Cardiac norepinephrine transporter protein expression is inversely correlated to chamber norepinephrine content.

Authors:  Erica A Wehrwein; Lindsay M Parker; Anna A Wright; John M Spitsbergen; Martin Novotny; Dagmar Babankova; Greg M Swain; Beth A Habecker; David L Kreulen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-06-18       Impact factor: 3.619

5.  Understanding the placebo effect in clinical trials for postural tachycardia syndrome.

Authors:  Victor C Nwazue; Amy C Arnold; Vidya Raj; Bonnie K Black; Italo Biaggioni; Sachin Y Paranjape; Carlos Orozco; William D Dupont; David Robertson; Satish R Raj
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-05       Impact factor: 2.557

6.  A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder.

Authors:  Chun-Hyung Kim; Maureen K Hahn; Yoosook Joung; Susan L Anderson; Angela H Steele; Michelle S Mazei-Robinson; Ian Gizer; Martin H Teicher; Bruce M Cohen; David Robertson; Irwin D Waldman; Randy D Blakely; Kwang-Soo Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-04       Impact factor: 11.205

7.  Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine.

Authors:  Toru Kobayashi; Kazuo Washiyama; Kazutaka Ikeda
Journal:  Neuropsychopharmacology       Date:  2010-03-10       Impact factor: 7.853

8.  Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy.

Authors:  Olayinka A Dina; Sachia G Khasar; Nicole Alessandri-Haber; Oliver Bogen; Xiaojie Chen; Paul G Green; David B Reichling; Robert O Messing; Jon D Levine
Journal:  Eur J Neurosci       Date:  2008-09-09       Impact factor: 3.386

9.  Dopamine synthesis and D3 receptor activation in pancreatic β-cells regulates insulin secretion and intracellular [Ca(2+)] oscillations.

Authors:  Alessandro Ustione; David W Piston
Journal:  Mol Endocrinol       Date:  2012-08-23

10.  Subcellular localization of the antidepressant-sensitive norepinephrine transporter.

Authors:  Heinrich J G Matthies; Qiao Han; Angela Shields; Jane Wright; Jessica L Moore; Danny G Winder; Aurelio Galli; Randy D Blakely
Journal:  BMC Neurosci       Date:  2009-06-23       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.